Australia markets closed

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
305.09-0.02 (-0.01%)
At close: 03:51PM GMT
Full screen
Previous close305.11
Bid0.00 x 0
Ask0.00 x 0
Day's range302.77 - 305.67
52-week range302.77 - 305.67
Avg. volumeN/A
Market cap784.078M
Beta (5Y monthly)0.44
PE ratio (TTM)0.32
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7

    BOSTON, January 17, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call".

  • Business Wire

    Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9

    BOSTON, January 04, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.

  • Business Wire

    Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA

    BOSTON, December 12, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex plans to initiate a sin